Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03440697 · ClinicalTrials.gov registry record
Pathogenetic Basis of Aortopathy and Aortic Valve Disease
A clinical trial of Aortic Valve Disease and Thoracic Aortic Aneurysm, sponsored by Yale University.
- Active
- Registry status
- 3,000
- Enrollment target
- 2
- Study locations
NCT03440697: Active study of Aortic Valve Disease and Thoracic Aortic Aneurysm, sponsored by Yale University.
NCT03440697 is a study of Aortic Valve Disease and Thoracic Aortic Aneurysm that is active but no longer recruiting, run by Yale University. The registered enrollment target is 3,000 participants, below the 18,417-participant average among 15 other Aortic Valve Disease trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03440697, a study of Aortic Valve Disease and Thoracic Aortic Aneurysm, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- 3,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
The main purpose of this study is to define the complex genetic and pathogenic basis of thoracic aortic aneurysm (TAA) and other forms of aortopathy and/or aortic valve disease by identifying novel disease-causing genes and by identifying important genetic modifiers for aortic and aortic valve disease severity.
Primary Outcome
Establish a biorepository with detailed phenotype information to facilitate a broad spectrum of current and future studies
Conditions Studied
Study Locations (2)
Georgia
- Childrens Healthcare of Atlanta - Atlanta
Indiana
- IU School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2015-12-10 |
| Est. Completion | 2030-12-31 |
What the registry record for NCT03440697 still lists
NCT03440697 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, below the 18,417-participant average among 15 other Aortic Valve Disease trials with a reported enrollment target (84% lower).
The record links to 10 conditions, with Aortic Valve Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03440697 reports a single indexed study location in Georgia, Indiana.
Frequently Asked Questions
What is clinical trial NCT03440697 about?
NCT03440697 is a clinical study titled "Pathogenetic Basis of Aortopathy and Aortic Valve Disease". The main purpose of this study is to define the complex genetic and pathogenic basis of thoracic aortic aneurysm (TAA) and other forms of aortopathy and/or aortic valve disease by identifying novel disease-causing genes and by identifying important genetic modifiers for aortic and aortic valve disea...
What is the current status of trial NCT03440697?
This trial is currently active not recruiting. The enrollment target is 3,000 participants. The study started on 2015-12-10. Estimated completion is 2030-12-31.
What conditions does trial NCT03440697 study?
This clinical trial studies the following conditions: Aortic Valve Disease, Thoracic Aortic Aneurysm, Thoracic Aortic Dissection, Thoracic Aortic Disease, Aortopathies.
Who is sponsoring clinical trial NCT03440697?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03440697 being conducted?
This trial has 2 study locations across Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aortic Valve Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03440697's enrollment target sits among peer trials
3,000 2nd of 15 the highest of 15 other Aortic Valve Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aortic Valve Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The JenaValve ALIGN-AR LVAD Registry
RECRUITING · NA
-
Quantification of Debris Captured Using TCEP During VIV TAVR With BVF
RECRUITING · NA
-
Valved Graft PMCF Study
RECRUITING
-
CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation
RECRUITING · NA
-
Prospective Long-Term Outcomes of a Standardized Ross Procedure
RECRUITING
-
SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI